UA97096C2 - Isolated antibody that specifically binds to trail receptor-2 (tr-2) - Google Patents
Isolated antibody that specifically binds to trail receptor-2 (tr-2)Info
- Publication number
- UA97096C2 UA97096C2 UAA200804023A UAA200804023A UA97096C2 UA 97096 C2 UA97096 C2 UA 97096C2 UA A200804023 A UAA200804023 A UA A200804023A UA A200804023 A UAA200804023 A UA A200804023A UA 97096 C2 UA97096 C2 UA 97096C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antibody
- specifically binds
- trail receptor
- isolated antibody
- relates
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to an isolated antibody that specifically binds to TRAIL Receptor-2 (TR-2), a polynucleotide encoding the antibody, a host cell, a method of obtaining an antibody. The invention further relates to a pharmaceutical composition comprising the antibody and to use of therapeutically effective amount of antibody for the preparation of medicinal agent for the treatment of cancer in patient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71343305P | 2005-08-31 | 2005-08-31 | |
PCT/US2006/033763 WO2007027713A2 (en) | 2005-08-31 | 2006-08-28 | Trail receptor 2 polypeptides and antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
UA97096C2 true UA97096C2 (en) | 2012-01-10 |
Family
ID=40079598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200804023A UA97096C2 (en) | 2005-08-31 | 2006-08-28 | Isolated antibody that specifically binds to trail receptor-2 (tr-2) |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101300273B (en) |
UA (1) | UA97096C2 (en) |
ZA (1) | ZA200802575B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8790663B2 (en) | 2009-04-03 | 2014-07-29 | Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences | Antigenic determinants of human death receptor DR5 |
CA2795325A1 (en) * | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
WO2013192594A2 (en) * | 2012-06-21 | 2013-12-27 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind c-met |
CN103333247B (en) * | 2013-05-30 | 2014-10-08 | 北京东方百泰生物科技有限公司 | Novel monoclonal antibody of VEGFR2 and preparation and application thereof |
CN106632607A (en) * | 2016-12-29 | 2017-05-10 | 华东理工大学 | Targeting survivin nano antibody as well as preparation method and application thereof |
CN108855003B (en) * | 2018-06-28 | 2021-01-05 | 南开大学 | Immunoadsorbent for removing inflammatory factors in blood and preparation method thereof |
CN114395034B (en) * | 2022-03-24 | 2022-08-05 | 中国科学院微生物研究所 | Human antibody for efficiently neutralizing novel coronavirus and application thereof |
WO2024153050A1 (en) * | 2023-01-17 | 2024-07-25 | 苏州永心生物科技有限公司 | Dr5 domain variant and use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI318983B (en) * | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
US20030180296A1 (en) * | 2001-12-20 | 2003-09-25 | Theodora Salcedo | Antibodies that immunospecifically bind to trail receptors |
-
2006
- 2006-08-28 CN CN200680040505.4A patent/CN101300273B/en not_active Expired - Fee Related
- 2006-08-28 UA UAA200804023A patent/UA97096C2/en unknown
-
2008
- 2008-03-20 ZA ZA200802575A patent/ZA200802575B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200802575B (en) | 2009-01-28 |
CN101300273B (en) | 2013-05-22 |
CN101300273A (en) | 2008-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA97096C2 (en) | Isolated antibody that specifically binds to trail receptor-2 (tr-2) | |
NO2017019I1 (en) | Diarylhydantoin compound, pharmaceutical composition and use thereof | |
IL197721A (en) | Isolated monoclonal antibody binding to human delta-like ligand 4 (dll4), pharmaceutical compositions comprising the same, polynucleotides encoding them and use thereof in the manufacture of medicaments for the treatment of cancer | |
WO2006053049A3 (en) | Herbal composition phy906 and its use in chemotherapy | |
UA94734C2 (en) | THERAPEUTIC ANTIBODIY WHICH BINDS TO b-AMYLOID PEPTIDE | |
MY158560A (en) | Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof | |
TW200716646A (en) | (S)-N-methylnaltrexone | |
WO2012024530A3 (en) | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods | |
MX2009006704A (en) | New compounds. | |
UA106194C2 (en) | Diagnosis and treatment of cancer using anti-ereg antibody | |
MX2011010390A (en) | Polymer-agent conjugates, particles, compositions, and related methods of use. | |
WO2006138608A3 (en) | Pharmaceutical compositions and use thereof | |
WO2007062413A3 (en) | Use of parp-1 inhibitors | |
AU2010266004A8 (en) | Method of treating cancer with Dll4 antagonist and chemotherapeutic agent | |
HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
MX2009006327A (en) | Heterocycle compounds and methods of use thereof. | |
WO2009002808A3 (en) | Quinazolinone compounds and methods of use thereof | |
MA32288B1 (en) | New antibodies useful for cancer treatment | |
WO2013071056A3 (en) | Combination drug therapy for the treatment of solid tumors | |
WO2009062576A3 (en) | Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | |
HK1105886A1 (en) | Pharmaceutical compositions comprising l-733060 for use in the treatment of cancer tumours l-733060 | |
UA99601C2 (en) | Use of an anti-cd151 antibody in the treatment of cancer | |
IL178939A (en) | Dual and triple combinations suitable for the synergistic treatment of breast cancer, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments or as medicaments for the treatment of breast cancer | |
UA99716C2 (en) | Antibody that specifically binds to human il-17 receptor a (il-17ra) | |
EP4101472A4 (en) | Anti-meflin antibody for use in treatment cancer in subject having cancer, and pharmaceutical composition including said antibody |